JPH10510433A - 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド - Google Patents

高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド

Info

Publication number
JPH10510433A
JPH10510433A JP9501254A JP50125497A JPH10510433A JP H10510433 A JPH10510433 A JP H10510433A JP 9501254 A JP9501254 A JP 9501254A JP 50125497 A JP50125497 A JP 50125497A JP H10510433 A JPH10510433 A JP H10510433A
Authority
JP
Japan
Prior art keywords
oligonucleotide
oligonucleotides
phosphorothioate
seq
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9501254A
Other languages
English (en)
Japanese (ja)
Inventor
クック，フィリップ・ダン
ホーク，グレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/468,447 external-priority patent/US5576302A/en
Priority claimed from US08/467,597 external-priority patent/US5607923A/en
Priority claimed from US08/469,851 external-priority patent/US5587361A/en
Priority claimed from US08/471,967 external-priority patent/US5599797A/en
Priority claimed from US08/470,129 external-priority patent/US5635488A/en
Priority claimed from US08/468,569 external-priority patent/US5620963A/en
Priority claimed from US08/471,966 external-priority patent/US5661134A/en
Priority claimed from US08/466,692 external-priority patent/US5654284A/en
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of JPH10510433A publication Critical patent/JPH10510433A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP9501254A 1995-06-06 1996-06-05 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド Pending JPH10510433A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US08/470,129 1995-06-06
US08/468,447 1995-06-06
US08/468,447 US5576302A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US08/471,967 1995-06-06
US08/467,597 US5607923A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US08/469,851 US5587361A (en) 1991-10-15 1995-06-06 Oligonucleotides having phosphorothioate linkages of high chiral purity
US08/469,851 1995-06-06
US08/471,967 US5599797A (en) 1991-10-15 1995-06-06 Oligonucleotides having phosphorothioate linkages of high chiral purity
US08/468,569 1995-06-06
US08/467,597 1995-06-06
US08/470,129 US5635488A (en) 1991-10-15 1995-06-06 Compounds having phosphorodithioate linkages of high chiral purity
US08/468,569 US5620963A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US08/471,966 1995-06-06
US08/466,692 1995-06-06
US08/471,966 US5661134A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US08/466,692 US5654284A (en) 1991-10-15 1995-06-06 Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
PCT/US1996/008757 WO1996039154A1 (fr) 1995-06-06 1996-06-05 Oligonucleotides de grande purete chirale ayant des liaisons phosphorothioate

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2000262871A Division JP2001103987A (ja) 1995-06-06 2000-08-31 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
JP2000262865A Division JP2001114798A (ja) 1995-06-06 2000-08-31 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド

Publications (1)

Publication Number Publication Date
JPH10510433A true JPH10510433A (ja) 1998-10-13

Family

ID=27575447

Family Applications (3)

Application Number Title Priority Date Filing Date
JP9501254A Pending JPH10510433A (ja) 1995-06-06 1996-06-05 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
JP2000262871A Pending JP2001103987A (ja) 1995-06-06 2000-08-31 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
JP2000262865A Pending JP2001114798A (ja) 1995-06-06 2000-08-31 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2000262871A Pending JP2001103987A (ja) 1995-06-06 2000-08-31 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
JP2000262865A Pending JP2001114798A (ja) 1995-06-06 2000-08-31 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド

Country Status (6)

Country Link
EP (1) EP0831854A4 (fr)
JP (3) JPH10510433A (fr)
AU (1) AU698739B2 (fr)
CA (1) CA2223103A1 (fr)
NO (1) NO975558L (fr)
WO (1) WO1996039154A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537644A (ja) * 2014-12-16 2017-12-21 ロシュ イノベーション センター コペンハーゲン エーエス キラル毒性のスクリーニング方法

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
AU8512598A (en) * 1997-07-25 1999-02-16 Hybridon, Inc. Oligonuclotides having 3' terminal stereospecific phosphorothioates
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US6242589B1 (en) * 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) * 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
AU764532B2 (en) * 1998-07-27 2003-08-21 University Of Iowa Research Foundation, The Stereoisomers of CpG oligonucleotides and related methods
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
KR20040074594A (ko) 2001-05-16 2004-08-25 마이크로로직스 바이오테크, 인코포레이티드 핵산을 기본으로 하는 화합물 및 이의 사용방법
EP1412750B1 (fr) 2001-06-26 2012-05-23 Senomyx, Inc. Récepteurs gustatifs sucrés hétero-oligomères t1r2-t1r3, lignées cellulaires exprimant lesdits récepteurs et utilisation de ces récepteurs pour identifier des composés gustatifs sucrés
US6916621B2 (en) 2002-03-27 2005-07-12 Spectral Genomics, Inc. Methods for array-based comparitive binding assays
EA010903B1 (ru) 2002-04-19 2008-12-30 Дайверса Корпорейшн Фосфолипазы, нуклеиновые кислоты, кодирующие их, и способы их получения и применения
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
PL378110A1 (pl) 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
EP3508578A1 (fr) 2003-03-06 2019-07-10 BASF Enzymes, LLC Amylases, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
AU2004277368B2 (en) 2003-03-07 2011-01-20 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and mehods for making and using them
EP1613733B1 (fr) 2003-04-04 2015-06-03 BASF Enzymes LLC Pectate lyases, acides nucleiques codant ces dernieres et procedes de fabrication et d'utilisation
CN101370819A (zh) 2003-07-02 2009-02-18 维莱尼姆公司 葡聚糖酶,编码它们的核酸以及制备和使用它们的方法
RU2419602C2 (ru) 2003-08-06 2011-05-27 Синомикс Инк. Новые ароматизирующие вещества, модификаторы вкуса, соединения, придающие вкус, усилители вкуса, соединения, придающие вкус "умами" или сладкий вкус, и/или усилители и их применение
CA2535526C (fr) 2003-08-11 2015-09-29 Diversa Corporation Laccases, acides nucleiques codant pour ces enzymes et procedes permettant de les produire et de les utiliser
EP2468853B1 (fr) 2004-06-16 2015-04-01 DSM IP Assets B.V. Procédé de décoloration enzymatique de la phéophytine
WO2006025995A2 (fr) 2004-07-27 2006-03-09 The Regents Of The University Of California Compositions et methodes faisant intervenir des mutants md-2 et des proteines chimeres
EP1869174B1 (fr) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyases, acides nucleiques codant pour celles-ci et methodes de fabrication et d'utilisation
AU2006227965B2 (en) 2005-03-15 2013-01-31 Bp Corporation North America Inc. Cellulases, nucleic acids encoding them and methods for making and using them
JP2009512421A (ja) 2005-08-15 2009-03-26 ヴァクシン インコーポレイテッド 非複製性ベクターワクチン投与による鳥類への免疫方法
CA2621083C (fr) 2005-08-30 2017-04-11 University Of Miami Immunomodulation des agonistes, des antagonistes et des immunotoxines du recepteur 25 du facteur de necrose tumorale (tnfr25)
EP1929044B1 (fr) 2005-09-02 2017-08-09 The Regents of The University of California Methodes et combinaisons de sondes pour la detection de melanomes
US20090324574A1 (en) 2006-02-02 2009-12-31 Verenium Corporation Esterases and Related Nucleic Acids and Methods
EP2447363B1 (fr) 2006-02-10 2014-02-12 Verenium Corporation Enzymes cellulolytiques, acides nucléiques les codant et leurs procédés de fabrication et d'utilisation
USRE45660E1 (en) 2006-02-14 2015-09-01 Bp Corporation North America Inc. Xylanases, nucleic acids encoding them and methods for making and using them
MX2008011477A (es) 2006-03-07 2008-09-23 Cargill Inc Aldolasas, acidos nucleicos que las codifican y metodos para hacerlas y usarlas.
CA2645225A1 (fr) 2006-03-07 2007-09-13 Verenium Corporation Aldolases, acides nucleiques les codant et procedes de
DK2010009T3 (en) 2006-04-21 2017-10-02 Senomyx Inc PROCEDURES FOR THE PREPARATION OF SOLID FLAVOR COMPOSITIONS
CN101528766A (zh) 2006-08-04 2009-09-09 维莱尼姆公司 葡聚糖酶、编码它们的核酸及制备和使用它们的方法
EP2617822A3 (fr) 2006-09-21 2013-10-16 Verenium Corporation Phytases, acides nucléiques encodant celles-ci et méthodes pour leur fabrication et leur utilisation
KR20090068266A (ko) 2006-09-21 2009-06-25 베레늄 코포레이션 포스포리파제, 그를 코딩하는 핵산 그리고 그를 제조 및 이용하는 방법
EP2069490B2 (fr) 2006-12-21 2018-02-21 BASF Enzymes LLC Amylases et glucoamylases, acides nucleiques les codant, et leurs procedes de fabrication
CA2674721C (fr) 2007-01-30 2018-04-03 Verenium Corporation Enzymes pour le traitement de matieres lignocellulosiques, des acides nucleiques les codant et procedes pour leur fabrication et leur utilisation
EA029920B1 (ru) 2007-04-27 2018-05-31 Те Риджентс Оф Те Юниверсити Оф Калифорния Кассета для экспрессии гетерологичных последовательностей в замыкающих клетках листьев и стеблей и ее применение
NZ584967A (en) 2007-10-03 2012-08-31 Verenium Corp Xylanases, nucleic acids encoding them and methods for making and using them
CA2702494A1 (fr) 2007-10-19 2009-04-23 The Regents Of The University Of California Compositions et procedes permettant d'ameliorer l'inflammation du sn, la psychose, le delire, le ptsd ou le sspt
EP2238261B1 (fr) 2008-01-03 2013-12-04 Verenium Corporation Isomérases, acides nucléiques codant pour celles-ci et leurs procédés de fabrication d'utilisation
EP2238242B9 (fr) 2008-01-03 2015-06-10 BASF Enzymes LLC Transférases et oxydoréductases, acides nucléiques codant pour celles-ci, et leurs procédés de fabrication et d'utilisation
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
EP2288379A4 (fr) 2008-05-19 2012-08-08 Advaxis Système de double distribution pour des antigènes hétérologues
US9084747B2 (en) 2009-11-11 2015-07-21 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors
EP2326707B1 (fr) 2008-08-12 2016-11-23 Evolva, Inc. Procédé de production d'isoprénoïdes
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
PL2326720T3 (pl) 2008-09-15 2018-08-31 F. Hoffmann-La Roche Ag Kompozycje i sposoby regulacji osmolarności komórki
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
WO2010123798A2 (fr) 2009-04-20 2010-10-28 Galenbio, Inc. Compositions de transfection de biomolécules dans des cellules
NZ596459A (en) 2009-05-21 2013-11-29 Verenium Corp Phytases, nucleic acids encoding them and methods for making and using them
IN2012DN00720A (fr) 2009-07-06 2015-06-19 Ontorii Inc
WO2011008768A1 (fr) 2009-07-13 2011-01-20 Wayne State University Ectodomaine de l’egfr modifié
AU2010279637B2 (en) 2009-08-03 2012-08-23 University Of Miami Method for in vivo expansion of T regulatory cells
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
US20120316080A1 (en) 2009-10-19 2012-12-13 Stichting Het Nederlands Kanker Instiuut Differentiation between brca2-associated tumours and sporadic tumours via array comparative genomic hybridization
EP2491140A1 (fr) 2009-10-19 2012-08-29 Stichting Het Nederlands Kanker Instituut Prédiction d'une réaction à un traitement contre le cancer par hybridation génomique comparative par jeux ordonnés d'échantillons
US20120322677A1 (en) 2009-10-19 2012-12-20 Stichting Het Nederlands Kanker Instituut Predicting benefit of anti-cancer therapy via array comparative genomic hybridization
EP2494076B1 (fr) 2009-10-26 2017-11-22 Abbott Molecular Inc. Détection d'anomalies chromosomiques associées au pronostic du cancer broncho-pulmonaire à grandes cellules
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011142818A1 (fr) 2010-05-10 2011-11-17 Abbott Laboratories Détection d'anomalies chromosomiques associées à cancer de l'endomètre
US20140018251A1 (en) 2010-09-20 2014-01-16 Stichting Het Nederlands Kanker Instituut Methods for Predicting Response to Anti-Cancer Therapy in Cancer Patients
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
US9234216B2 (en) 2010-10-06 2016-01-12 Bp Corporation North America Inc. Variant CBH I polypeptides
WO2012083240A2 (fr) 2010-12-16 2012-06-21 Dana-Farber Cancer Institute, Inc. Puce d'oligonucléotides pour le typage tissulaire
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
US9745631B2 (en) 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2013124740A2 (fr) 2012-02-23 2013-08-29 Stichting Vu-Vumc Dysfonctionnement de la protéine brca et signatures arnm utiles dans l'identification de patients atteints de tumeurs dues au dysfonctionnement de la protéine brca et prévision des bénéfices d'une thérapie anti-cancer sur des patients atteints de cancer
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
EP2855698A4 (fr) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc Ciblage de la voie allant de la glutamine au pyruvate pour traiter un cancer associé à l'oncogène kras
WO2013192545A1 (fr) 2012-06-22 2013-12-27 The Regents Of The University Of California Compositions et procédés pour médier le développement des stomates chez les plantes en réponse au dioxyde de carbone et applications de manipulation de la tolérance à la sécheresse chez les plantes
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CA2879066C (fr) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucleique chiral
WO2014012090A1 (fr) 2012-07-13 2014-01-16 The Broad Institute, Inc. Traîneaux moléculaires comprenant une séquence d'acides aminés à charges positives et cargaison moléculaire et utilisations correspondantes
WO2014012081A2 (fr) 2012-07-13 2014-01-16 Ontorii, Inc. Contrôle chiral
WO2014014518A1 (fr) 2012-07-18 2014-01-23 Dana-Farber Cancer Institute, Inc. Méthodes de traitement, de prévention et de prédiction du risque de développer le cancer du sein
CN116622704A (zh) 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
WO2014093709A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés
EP3064585B1 (fr) 2012-12-12 2020-02-05 The Broad Institute, Inc. Fabrication et optimisation de systèmes, procédés et compositions d'enzyme améliorés pour la manipulation de séquences
IL293526A (en) 2012-12-12 2022-08-01 Harvard College Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
EP2931899A1 (fr) 2012-12-12 2015-10-21 The Broad Institute, Inc. Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
KR20150105634A (ko) 2012-12-12 2015-09-17 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 개선된 시스템, 방법 및 효소 조성물의 유전자 조작 및 최적화
AU2014205366B2 (en) 2013-01-09 2018-12-20 Eckhard R. Podack Compositions and methods for the regulation of T regulatory cells using Tl1a-Ig fusion protein
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
CN106062197A (zh) 2013-06-17 2016-10-26 布罗德研究所有限公司 用于序列操纵的串联指导系统、方法和组合物的递送、工程化和优化
ES2767318T3 (es) 2013-06-17 2020-06-17 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para generar modelos y actuar sobre enfermedades y trastornos de células posmitóticas
AU2014281027A1 (en) 2013-06-17 2016-01-28 Massachusetts Institute Of Technology Optimized CRISPR-Cas double nickase systems, methods and compositions for sequence manipulation
EP3011034B1 (fr) 2013-06-17 2019-08-07 The Broad Institute, Inc. Administration, utilisation et applications thérapeutiques de systèmes crispr-cas et compositions pour cibler les troubles et maladies en utilisant des éléments viraux
SG11201510284XA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery and use of the crispr-cas systems, vectors and compositions for hepatic targeting and therapy
US10130590B2 (en) 2013-10-01 2018-11-20 Dana-Farber Cancer Institute, Inc. Methods of treating cancer with atovaquone-related compounds
WO2015057671A1 (fr) 2013-10-14 2015-04-23 The Broad Institute, Inc. Facteurs de transcription artificiels comportant un domaine coulissant et leurs utilisations
WO2015058052A1 (fr) 2013-10-18 2015-04-23 The Broad Institute Inc. Cartographie spatiale et cellulaire de biomolécules in situ par séquençage à haut débit
WO2015089364A1 (fr) 2013-12-12 2015-06-18 The Broad Institute Inc. Structure cristalline d'un système crispr-cas, et ses utilisations
BR112016013213A2 (pt) 2013-12-12 2017-12-05 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para visar distúrbios e doenças usando componentes de administração de partículas
KR20160089530A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 Ｈｂｖ 및 바이러스 질병 및 질환을 위한 ｃｒｉｓｐｒ­ｃａｓ 시스템 및 조성물의 전달，용도 및 치료적 적용
BR112016013520A2 (pt) 2013-12-12 2017-10-03 Broad Inst Inc Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos
KR20160089527A (ko) 2013-12-12 2016-07-27 더 브로드 인스티튜트, 인코퍼레이티드 게놈 편집을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 조성물의 전달, 용도 및 치료적 응용
EP4219699A1 (fr) 2013-12-12 2023-08-02 The Broad Institute, Inc. Ingénierie de systèmes, procédés et compositions de guide optimisées avec de nouvelles architectures pour la manipulation de séquence
EP3095460A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
KR20220106232A (ko) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 키랄 디자인
US9701743B2 (en) 2014-02-20 2017-07-11 Allergan, Inc. Complement component C5 antibodies
KR20160126054A (ko) 2014-02-27 2016-11-01 알러간, 인코포레이티드 보체 인자 Bb 항체
BR112016020987B1 (pt) 2014-03-12 2023-11-14 Western Sydney Local Health District Método de identificação de receptores de aloenxerto renal e método de seleção de receptor do aloenxerto renal
US10350264B2 (en) 2014-03-27 2019-07-16 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin
EP3161165B1 (fr) 2014-06-26 2020-11-18 Icahn School of Medicine at Mount Sinai Procédé permettant de diagnostiquer une forme infraclinique et clinique du rejet aigu par analyse de séries de gènes prédictifs, agents therapeutiques pour le traitement et jeux pour determiner l'expression
US9907849B2 (en) 2014-07-18 2018-03-06 Advaxis, Inc. Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer
WO2016028682A1 (fr) 2014-08-17 2016-02-25 The Broad Institute Inc. Édition du génome à l'aide de nickases cas9
WO2016049024A2 (fr) 2014-09-24 2016-03-31 The Broad Institute Inc. Administration, utilisation et applications thérapeutiques des systèmes crispr-cas et compositions permettant de modéliser la concurrence de multiples mutations cancéreuses in vivo
WO2016049251A1 (fr) 2014-09-24 2016-03-31 The Broad Institute Inc. Administration, utilisation et applications thérapeutiques de systèmes crispr-cas et compositions de modélisation de mutations dans des leucocytes
WO2016049163A2 (fr) 2014-09-24 2016-03-31 The Broad Institute Inc. Utilisation et production d'animaux transgéniques chd8 +/- possédant des phénotypes de comportement caractéristiques d'un trouble du spectre autistique
WO2016049258A2 (fr) 2014-09-25 2016-03-31 The Broad Institute Inc. Criblage fonctionnel avec systèmes crisp-cas fonctionnels optimisés
WO2016094872A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Guides désactivés pour facteurs de transcription crispr
WO2016094874A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Guides escortés et fonctionnalisés pour systèmes crispr-cas
WO2016094880A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Administration, utilisation et applications thérapeutiques de systèmes crispr et compositions pour l'édition de génome de cellules souches hématopoïétiques (hsc)
EP3230451B1 (fr) 2014-12-12 2021-04-07 The Broad Institute, Inc. Arn guides protégés (pgrnas)
WO2016100974A1 (fr) 2014-12-19 2016-06-23 The Broad Institute Inc. Identification non biaisée de cassures bicaténaires et réarrangement génomique par séquençage de capture d'insert à l'échelle du génome
WO2016106236A1 (fr) 2014-12-23 2016-06-30 The Broad Institute Inc. Système de ciblage d'arn
WO2016106244A1 (fr) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr présentant ou associé avec un domaine de déstabilisation
WO2016108926A1 (fr) 2014-12-30 2016-07-07 The Broad Institute Inc. Modélisation et dépistage génétique in vivo, médiés par crispr, de la croissance tumorale et de métastases
EP3298172B1 (fr) 2015-05-22 2023-07-26 The Regents of The University of California Détermination du risque de récurrence du cancer de la prostate
WO2016205728A1 (fr) 2015-06-17 2016-12-22 Massachusetts Institute Of Technology Enregistrement d'événements cellulaires médié par crispr
WO2016205745A2 (fr) * 2015-06-18 2016-12-22 The Broad Institute Inc. Tri cellulaire
EP3666895A1 (fr) 2015-06-18 2020-06-17 The Broad Institute, Inc. Nouveaux systèmes et enzymes de crispr
AU2016279062A1 (en) 2015-06-18 2019-03-28 Omar O. Abudayyeh Novel CRISPR enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CN116814590A (zh) 2015-10-22 2023-09-29 布罗德研究所有限公司 Vi-b型crispr酶和系统
WO2017075292A1 (fr) 2015-10-28 2017-05-04 The Broad Institute, Inc. Systèmes et procédés permettant de déterminer des abondances relatives de biomolécules
WO2017075294A1 (fr) 2015-10-28 2017-05-04 The Board Institute Inc. Dosages utilisés pour le profilage de perturbation massivement combinatoire et la reconstruction de circuit cellulaire
US20190233814A1 (en) 2015-12-18 2019-08-01 The Broad Institute, Inc. Novel crispr enzymes and systems
AU2017257274B2 (en) 2016-04-19 2023-07-13 Massachusetts Institute Of Technology Novel CRISPR enzymes and systems
US20210155911A1 (en) 2016-04-19 2021-05-27 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3445853A1 (fr) 2016-04-19 2019-02-27 The Broad Institute, Inc. Complexes cpf1 à activité d'indel réduite
WO2017219027A1 (fr) 2016-06-17 2017-12-21 The Broad Institute Inc. Systèmes et orthologues crispr de type vi
US20210222164A1 (en) 2016-06-29 2021-07-22 The Broad Institute, Inc. Crispr-cas systems having destabilization domain
EP3500670A4 (fr) 2016-08-17 2020-08-19 The Broad Institute, Inc. Nouveaux systèmes et enzymes crispr
US11840694B2 (en) 2016-10-17 2023-12-12 Nanyang Technological University Truncated CRISPR-Cas proteins for DNA targeting
EP4361261A2 (fr) 2017-03-15 2024-05-01 The Broad Institute Inc. Nouvelles enzymes crispr orthologues cas13b et systèmes
BR112019021378A2 (pt) 2017-04-12 2020-05-05 Massachusetts Inst Technology ortólogos de crispr tipo vi inovadores e sistemas
WO2018208910A1 (fr) 2017-05-09 2018-11-15 The Broad Institute Inc. Fonction du microbiome intestinal prédisant la réponse à une thérapie biologique anti-intégrine dans des maladies intestinales inflammatoires
CA3067951A1 (fr) 2017-06-23 2018-12-27 Inscripta, Inc. Nucleases guidees par acide nucleique
WO2019089803A1 (fr) 2017-10-31 2019-05-09 The Broad Institute, Inc. Procédés et compositions pour l'étude de l'évolution cellulaire
WO2019113506A1 (fr) 2017-12-07 2019-06-13 The Broad Institute, Inc. Procédés et compositions pour multiplexer un séquençage de noyaux isolés et de cellules isolées
WO2019204267A1 (fr) 2018-04-16 2019-10-24 Icahn School Of Medicine At Mount Sinai Procédé et kits pour la prédiction d'un rejet aigu et d'une perte d'allogreffe rénale à l'aide de signatures transcriptomiques de pré-transplantation dans le sang du receveur
US20210317429A1 (en) 2018-08-20 2021-10-14 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
WO2020236967A1 (fr) 2019-05-20 2020-11-26 The Broad Institute, Inc. Mutant de délétion de crispr-cas aléatoire
US11767528B2 (en) 2019-08-16 2023-09-26 Massachusetts Institute Of Technology Targeted trans-splicing using CRISPR/Cas13
EP4171199A1 (fr) 2020-06-25 2023-05-03 Mycotechnology, Inc. Protéine sucrée à partir de truffe
US11248265B1 (en) 2020-11-19 2022-02-15 Clear Labs, Inc Systems and processes for distinguishing pathogenic and non-pathogenic sequences from specimens
CN117279502A (zh) 2020-11-20 2023-12-22 雷维维科公司 用于异种移植的生长激素受体敲除的多转基因猪
WO2022271548A2 (fr) 2021-06-23 2022-12-29 Massachusetts Institute Of Technology Compositions, procédés et systèmes pour l'administration d'un matériel d'édition de gènes à des cellules
US20230255185A1 (en) 2021-09-20 2023-08-17 Revivicor, Inc. Multitransgenic pigs comprising ten genetic modifications for xenotransplantation
WO2023141602A2 (fr) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
WO2023185697A2 (fr) 2022-03-29 2023-10-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions et méthodes pour le traitement de l'amyloïdose de la transthyrétine
GB202208575D0 (en) 2022-06-13 2022-07-27 Univ Edinburgh Activation of noncoding host gene loci
WO2024020346A2 (fr) 2022-07-18 2024-01-25 Renagade Therapeutics Management Inc. Composants d'édition génique, systèmes et procédés d'utilisation
WO2024044723A1 (fr) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Rétrons modifiés et méthodes d'utilisation
WO2024061296A2 (fr) 2022-09-22 2024-03-28 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions et méthodes de traitement de l'hypercholestérolémie et/ou d'une maladie cardiovasculaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506212A (en) * 1990-01-11 1996-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
WO1995006659A1 (fr) * 1992-07-01 1995-03-09 Isis Pharmaceuticals, Inc. Nucleosides et oligonucleosides a fonction(s) amine
EP0544716B1 (fr) * 1990-08-14 2002-12-18 Isis Pharmaceuticals, Inc. Modulation par des oligonucleotides de l'adherence cellulaire
WO1994008003A1 (fr) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. INHIBITION DU GENE ras A L'AIDE D'OLIGONUCLEOTIDES NON CODANTS
WO1993008296A1 (fr) * 1991-10-15 1993-04-29 Isis Pharmaceuticals, Inc. Oligonucleotides presentant des liaisons phosphorees chirales
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
DK0662157T3 (da) * 1992-09-10 2001-08-27 Isis Pharmaceuticals Inc Præparater og fremgangsmåde til behandling af Hepatitis C-virus-associerede sygdomme

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017537644A (ja) * 2014-12-16 2017-12-21 ロシュ イノベーション センター コペンハーゲン エーエス キラル毒性のスクリーニング方法

Also Published As

Publication number Publication date
CA2223103A1 (fr) 1996-12-12
AU698739B2 (en) 1998-11-05
NO975558D0 (no) 1997-12-02
EP0831854A4 (fr) 2001-01-24
JP2001114798A (ja) 2001-04-24
JP2001103987A (ja) 2001-04-17
NO975558L (no) 1998-01-26
AU6252896A (en) 1996-12-24
WO1996039154A1 (fr) 1996-12-12
EP0831854A1 (fr) 1998-04-01

Similar Documents

Publication Publication Date Title
JPH10510433A (ja) 高いキラル純度のホスホロチオエート結合を有するオリゴヌクレオチド
US5607923A (en) Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5599797A (en) Oligonucleotides having phosphorothioate linkages of high chiral purity
US5661134A (en) Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5576302A (en) Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US5587361A (en) Oligonucleotides having phosphorothioate linkages of high chiral purity
US5620963A (en) Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US5635488A (en) Compounds having phosphorodithioate linkages of high chiral purity
CA2121144C (fr) Oligonucleotides ayant des liaisons phosphore chirales
US5506212A (en) Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5521302A (en) Process for preparing oligonucleotides having chiral phosphorus linkages
US5852188A (en) Oligonucleotides having chiral phosphorus linkages
JP4383720B2 (ja) オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性
JP3529135B2 (ja) 特定のｒｎａ鎖の切断方法
JP3585583B2 (ja) 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
US5654284A (en) Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
EP0431523A2 (fr) Composés de nucléotides modifiés
JP2001002696A (ja) ギャップを有する２′修飾オリゴヌクレオチド
JP2005522997A (ja) 交代セグメントを含むオリゴヌクレオチド及びその用途
AU2003202376A1 (en) Oligonucleotides comprising alternating segments and uses thereof
JPH09505307A (ja) 多キラル合成フォスホネートオリゴマー類
KR100257972B1 (ko) 높은 키랄 순도의 포스포로티오에이트 결합기를 가지는 올리고뉴클레오티드
EP0931090A1 (fr) Vecteurs oligonucleotidiques chimeres ameliores
WO1997014708A1 (fr) Oligonucleotides contenant des derives nucleosides a substitution thiol et procedes d'utilisation desdits oligonucleotides